Development of Dendritic Cell-Based Immunotherapy Targeting Tumor Blood Vessels in a Mouse Model of Lung Metastasis
Open accessAbstract
Tumor blood vessels supply cancer tissues with oxygen and nutrients, and it was therefore believed that inhibition of angiogenesis would induce tumor regression. In fact, the situation is complicated by the presence of normal blood vessels in cancer tissues such as carcinomas and sarcomas as well as abnormal vessels. Here, we describe the development of a dendritic cell (DC)-based immunotherapy which targets tumor endothelial cells (TECs) rather than normal endothelial cells (ECs) or cancer cells themselves. After density gradient centrifugation, the TEC-rich fraction from lungs invaded by B16 melanoma cells was separated from the endothelial cell (EC)-rich fraction on the basis of positivity for angiotensin-converting enzyme (ACE) activity. Prophylactic vaccination with DCs pulsed with lysates of TECs isolated from lungs with metastases significantly suppressed lung metastasis in this B16/BL6 mouse melanoma model. This suggests that DC-based vaccine therapy targeting TECs in cancers tissue could show promise as an effective therapy for distant metastasis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TECs can be used for cancer vaccine development.
“Moreover, TEC can be used for cancer vaccine development.”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [54]
Prophylactic vaccination with dendritic cells pulsed with lysates of TECs positive for angiotensin-converting enzyme activity, isolated from lung with metastases, significantly suppresses lung metastasis in the B16/BL6 mouse melanoma model.
“Prophylactic vaccination with DCs pulsed with lysates of TECs (positive for angiotensin-converting enzyme (ACE) activity) isolated from the lung with metastases was shown to significantly suppress lung metastasis in the B16/BL6 mouse melanoma model.”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · see citing works
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,598 · see citing works
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617 · see citing works
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509 · see citing works
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,741 · see citing works
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · see citing works
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.
Weidner, N., Carroll, P. R., Flax, J. D., Blumenfeld, W., & Folkman, J. (1993) · PubMed Central · Cited by 1,620 · see citing works
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism · doi:10.2174/138920009788897975 · Cited by 630 · see citing works
Asahara, T., Bauters, C., Zheng, L. P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J. F., & Isner, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.9.365 · Cited by 597 · see citing works
Cell surface tumor endothelial markers are conserved in mice and humans.
Carson-Walter, E. B., Watkins, D. N., Nanda, A., Vogelstein, B., Kinzler, K. W., & Croix, B. S. (2001) · PubMed · Cited by 410 · see citing works
Angiogenesis and colonization in the tumor metastatic process: basic and applied advances
Weinstat‐Saslow, D., & Steeg, P. S. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.6.7513289 · Cited by 155 · see citing works
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Herbst, R. S., & Bunn, P. A. (2003) · PubMed · Cited by 138 · see citing works
Camussi, G., Montrucchio, G., Lupia, E., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1302 · Cited by 87 · see citing works
Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas
Lazzereschi, D., Sambuco, L., Scalzo, C. C., Ranieri, A., Mincione, G., Nardi, F., & Colletta, G. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980610)76:6 · Cited by 75 · see citing works
Mangoni, M., Vozenin, M., Biti, G., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.236 · Cited by 42 · see citing works
Fournier's Gangrene as a Possible Side Effect of Bevacizumab Therapy for Resected Colorectal Cancer
Gamboa, E. O., Rehmus, E. H., & Haller, N. A. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.008 · Cited by 25 · see citing works
Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer
Steins, M. B., Reinmuth, N., Bischoff, H. G., et al. (2010) · Onkologie · doi:10.1159/000322214 · Cited by 18 · see citing works
Isolation and Properties of Tumor‐derived Endothelial Cells from Rat KMT‐17 Fibrosarcoma
Utoguchi, N., Dantakean, A., Makimoto, H., et al. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb03039.x · Cited by 16 · see citing works
Self-citationNomura, T., Hirata, K., 卓人, 嶋., et al. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00145 · Cited by 14 · see citing works
Self-citationNovel protein engineering strategy for creating highly receptor-selective mutant TNFs
Nomura, T., Abe, Y., Kamada, H., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.052 · Cited by 8 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784 · see citing works
“DC-based vaccines that target TECs in tumor cells are likely to have effective therapeutic outcomes on distant metastasis [54].”
Background
- Authors
- Nomura, T., Yamakawa, M., Shimaoka, T., Hirai, T., Koizumi, N., Maruyama, K., & Utoguchi, N.
- Affiliations
- Teikyo University (JP)
- Showa Pharmaceutical University (JP)
- Faculty of Pharma-Sciences, Teikyo University
- Venue
- Biological and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2019-04-01
- Volume
- 42
- Issue
- 4
- Pages
- 645-648
- ISSN
- 0918-6158 (ISSN-L)
- 1347-5215
- OpenAlex
- W2931500499
- Cited by
- 6
- References
- 20
- Citations by year
- 2024: 1 · 2023: 3 · 2020: 1 · 2019: 1
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Biological and Pharmaceutical Bulletin (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (2013−2017)
- Japan Society for the Promotion of Science (23501288, 19590160, 22890192, 15K06881, 17K18115, 24790050, 16790110)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
- Keywords
- dendritic cell immunotherapy, tumor endothelial cells, lung metastasis, B16 melanoma, prophylactic vaccination, angiotensin-converting enzyme, tumor angiogenesis, tumor vasculature targeting, metastasis suppression
- MeSH terms
- Animals, Dendritic Cells, Immunotherapy, Peptidyl-Dipeptidase A, Lung, Lung Neoplasms, Melanoma, Experimental, Mice, Inbred C57BL, Neovascularization, Pathologic, Cancer Vaccines, Endothelial Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
